Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease"
Alzheimers Dement
.
2006 Jul;2(3):140-2.
doi: 10.1016/j.jalz.2006.03.017.
Author
Eric R Siemers
1
Affiliation
1
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. esiemers@lilly.com
PMID:
19595871
DOI:
10.1016/j.jalz.2006.03.017
No abstract available
Publication types
Comment